Market Research Blog

According to a recent lateral flow assays market report by Future Market Insights (FMI), the lateral flow assays market was valued at US$ 11 Bn in 2021, is projected to reach US$ 12.5 Bn by 2026, and is anticipated to grow at a CAGR of around 2% over the projected period of 2022-2032.

The high rate of infectious diseases around the world, explosive growth in the geriatric population, escalating demand for point-of-care testing, and increased use of home-based rapid lateral flow devices are all boosting lateral flow assays market forward. The significant restraints are doctors’ and patients’ reluctance to change existing diagnostic techniques and the low accuracy of lateral flow assays.

The affordable cost of lateral flow assays devices and the fact that no trained personnel is required to run the tests are two factors driving up demand for lateral flow assays-based devices for COVID-19 testing. The growing adoption of kits & reagents due to innovations and benefits of lateral flow assays rapid tests over laboratory tests the high number of lateral flow assay rapid detection kits launched by healthcare companies, predominantly for lateral flow assay COVID-19 testing, are all factors contributing to the large share of the kits & reagents segment. Sandwich assays have a considerable part of the lateral flow assays market due to the growing use of sandwich assays in medical testing and the benefits of sandwich assays.

Despite the fact that lateral flow assay tests are simple to implement and less affordable than laboratory testing, they are less reliable. Due to the apparently limited accuracy of the lateral flow assay kit, most doctors and patients prefer molecular studies to fast tests for more accurate COVID-19 diagnosis. As a result, major diagnostic lateral flow assays market participants are concentrating their efforts on developing more laboratory-based infectious disease testing solutions.

Infectious disease lateral flow assays diagnostics, cardiac disease diagnosis, and veterinary applications are typical applications for lateral flow tests. However, the use of lateral flow technology has grown in various new applications in recent years. Potential applications for lateral flow tests include saliva diagnostics, behavioural health, agriculture (crop quality testing), biowarfare (anthrax detection), environmental testing, and food microbiology. Lateral flow assay (immunochromatography tests/lateral flow immunoassays) technologies continue to dominate the point of care diagnostic market through 2024. The acquisition and validation of vital reagents are one of the most challenging elements of producing lateral flow assay tests. Antibodies used in assays must be evaluated for accuracy, specificity, stability, and reproducibility, as any reagent flaws can cause the lateral flow assay to fail. Another obstacle is lateral flow assays diagnostics after an antibody or antibody pair has been found.

Key Takeaways

• The Kits & Reagents segment is anticipated to grow at a rapid CAGR of 5.3% during the forecast period.
• The clinical testing segment accounted for 90.9% of the lateral flow tests market.
• With a lateral flow tests market share of 70.9% in 2020, sandwich assays dominated the lateral flow tests market.
• Blood samples were the most preferred, with a 53.1% lateral flow tests market share.
• The hospitals and clinics segment was the most favoured, with a lateral flow tests market share of 37.6%.
• China, the world’s second-largest economy, is expected to reach a lateral flow tests market size of US$917 million in 2027, with an annual growth rate of 8.8%.
• Within Europe, Germany is expected to show a lateral flow tests market growth at a 4.8% compound annual growth rate (CAGR), while the rest of the European market will reach US$917 million by 2027.
• The Asia Pacific region is expected to increase at a CAGR of 4.2% during the forecast period.

Get Sample PDF Brochure: 

https://www.futuremarketinsights.com/reports/sample/rep-gb-14271

Competitive Landscape

Some companies have increased their lateral flow tests market share through various strategies such as mergers and acquisitions. In contrast, others invent new diagnostic market test methods and provide innovative goods to maintain their market share.

Key Segments

By Application:

• Clinical Testing
• Veterinary Diagnostics
• Food Safety & Environmental Testing
• Drug Development & Quality Testing

By Technique:

• Sandwich Assays
• Competitive Assays
• Multiplex Detection Assays

By Sample Type:

• Blood Samples
• Urine Samples
• Saliva Samples
• Others
• By Type
• Kits & Reagents
• Lateral Flow Readers

By End User:

• Hospitals & Clinics
• Diagnostics Laboratories
• Home Care Settings
• Pharmaceuticals & Biotechnology Companies
• Others

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East and Africa

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-14271

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Summary of Statistics

1.3. Key Market Characteristics & Attributes

1.4. Fact.MR Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Risks and Trends Assessment

3.1. Risk Assessment

3.1.1. COVID-19 Crisis and Impact on Lateral Flow Assays Demand

3.1.2. COVID-19 Impact Benchmark with Previous Crisis

3.1.3. Impact on Market Value (US$ Mn)

3.1.4. Assessment by Key Countries

3.1.5. Assessment by Key Market Segments

3.1.6. Action Points and Recommendation for Suppliers

3.2. Key Trends Impacting the Market

3.3. Formulation and Product Development Trends

4. Market Background

4.1. Lateral Flow Assays Market, by Key Countries

4.2. Lateral Flow Assays Market Opportunity Assessment (US$ Mn)

4.2.1. Total Available Market

4.2.2. Serviceable Addressable Market

4.2.3. Serviceable Obtainable Market

4.3. Market Scenario Forecast

4.3.1. Demand in optimistic Scenario

4.3.2. Demand in Likely Scenario

4.3.3. Demand in Conservative Scenario

4.4. Investment Feasibility Analysis

4.4.1. Investment in Established Markets

4.4.1.1. In Short Term

4.4.1.2. In Long Term

4.4.2. Investment in Emerging Markets

4.4.2.1. In Short Term

4.4.2.2. In Long Term

4.5. Forecast Factors – Relevance & Impact

4.5.1. Top Companies Historical Growth

4.5.2. Growth in Automation, By Country

4.5.3. Lateral Flow Assays Adoption Rate, By Country

4.6. Market Dynamics

4.6.1. Market Driving Factors and Impact Assessment

4.6.2. Prominent Market Challenges and Impact Assessment

4.6.3. Lateral Flow Assays Market Opportunities

4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors

5.1. Manufacturers’ Focus on Low Penetration High Growth Markets

5.2. Banking on with Segments High Incremental Opportunity

5.3. Peer Benchmarking

Inquire Before Buying This Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-14271

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The global demand for drug discovery services market is expected to rise at a 14.5% CAGR to acquire a valuation of US$ 50.9 Bn by the end of forecast period 2022-232. The global drug discovery services market size was valued at US$ 15.5 Bn in 2021 and is projected to reach a valuation of US$ 32 Bn by 2026

The global drug research services industry is booming as a result of increased funding for research and innovation in a multitude of segments. The drug discovery process is a significant part of the pharmaceutical sector. The study on drug discovery services market finds that the efforts of researchers towards the development of new drug prototypes have popularized outsourcing of drug discovery services. Moreover, growing spending on research and the development of novel medications for the treatment of deadly diseases and disorders has stimulated the demand for drug discovery platform. Pharmaceutical and biopharmaceutical businesses are opting for seamlessly engaged and multifunctional solution providers for drug discovery research, from the developing phase to the late testing stages. Emerging trends in drug discovery services market portends that pharmaceutical companies opt for outsourcing as a key choice to offset the shortage of in-house manpower required for new product development, as pharmaceutical businesses face great pressure to reduce overhead costs.

Restrictive laws regulating drug research and animal testing are projected to limit drug distribution to some extent. Drug discovery service organizations are facing restrictions due to a limitation of trained employees. The use of animals in pharmaceutical research is governed by strict laws. Mice, rats, fish, amphibians, and reptiles are the most common animals utilized in scientific studies. Considerations over the ethical use of animal experimentation have prompted countries to enact animal safety and use statutes, which raises a number of impediments to the future of drug discovery services market.

The drug discovery trends indicate that Biologics, such as proteins, peptides, and monoclonal antibodies, account for more than half of the therapeutic possibilities in the initial cycle. In 2022, biologics are estimated to make up for approximately half of the income earned by the top 100 pharmaceutical drugs. As per the global market study on drug discovery services, they provide the drug discovery services market with highest growth potential through the forecast period.

Despite the fact that small-molecule pharmaceutical companies monopolize the global pharmaceutical market, players working with biologics, biosimilars, and large-molecule drugs are tapping into the drug discovery services market opportunities primarily to introduce new biologic-based treatments and rising revenue from current biologics.

All-in-all, the drug discovery services market is expected to reach a valuation of US$ 32 Bn by 2026.

Get Sample PDF Brochure: 

https://www.futuremarketinsights.com/reports/sample/rep-gb-14258

Key Takeaways

• The drug discovery services market is divided into two types–chemistry and biology services. In 2020, the chemistry drug discovery services category held the greatest proportion of the market.
• Small molecules are expected to occupy the largest share of revenue when compared to biologics. Drug discovery statistics specify that small molecules are expected to generate more than US$ 10,800 million in revenue by the end of 2026.
• The oncology category is predicted to have the leading position, owing to the increasing number of cancer patients around the world.
• In comparison to other innovative drug discovery services, Hit-To-Lead identification is expected to acquire the most traction.
• As the most revenue generating phase, several CROs are already delivering Hit-to-lead identification services to pharmaceutical corporations.

“The Asia Pacific drug discovery services market growth is anticipated to be the highest during the projected duration, owing to expansions happening in the pharmaceutical and biopharmaceutical industry. A high proportion of contract research organizations (CROs), government incentives, high research and development in pharmaceutical industry, and the involvement of less restrictive standards for drug discovery programs (particularly in terms of using animals for research) across several APAC countries are some drivers sustaining the healthy growth of the drug discovery services market.”, opines a seasoned FMI analyst.

Competitive Landscape

The COVID-19 pandemic highlighted the importance of outsourcing drug discovery services for companies and research groups in North America. These companies are now working together with the government to facilitate the drug discovery process.

• Existencia, a business using artificial intelligence in drug discovery, announced a collaboration with Diamond Light Source and Scripps Research on March 31, 2020, to identify COVID-19 antiviral treatments.
• Samsung Biologics, a South Korean pharmaceutical business, has signed a long-term partnership with Eli Lilly and Company to develop bamlanivimab, an investigational COVID-19 virus-neutralizing antibody.

Genesis Therapeutics and Genentech announced a multi-target drug discovery AI partnership in November 2020. Genesis’ graph machine learning and drug discovery skills will be used in this cooperation to identify novel drug candidates for therapeutic targets in a variety of illness domains.

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-14258

Key Segment

By Process:

• Target Selection
• Target Validation
• Hit-to-Lead Identification
• Lead Optimization
• Candidate Validation

By Type:

• Chemistry Services
• Biology Services

By Drug Type:

• Small Molecules Drugs
• Biologics Drugs

By Therapeutic Area:

• Neurology
• Infectious and Immune System Diseases
• Digestive System Diseases
• Oncology
• Other Therapeutic Area

By End User:

• Pharmaceutical & Biotechnology Companies
• Academic Institutes
• Manufacturing
• Other End Users

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East and Africa

Inquire Before Buying This Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-14258

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

According to a recent study by Future Market Insights (FMI), the cold disposable biopsy forceps market is expected to witness high growth during the forecast period. The market value is slated to increase from US$ 505.1 Mn in 2020 to over US$ 1.2 Bn by 2031 at 8.4% CAGR over the forecast period (2021-2031).

The cold disposable biopsy forceps market will register high demand due the rising prevalence bronchitis and gastrointestinal disorders such as IBD and GERD among the geriatric population and the increasing awareness towards endoscopic procedures. There is also a rise in the adoption of disposable biopsy forceps that to be reliable for test sampling expects to gain popularity.

At present, the minimally-invasive technology, with the endoscope system at the core, has been extended to obstetrics, general surgery, otolaryngology, gynecology, thoracic surgery, urology, pediatrics, and other departments. Minimally-invasive endoscopic technology has become an indispensable technology for the diagnosis and treatment of chronic diseases associated with breathing, digestion, urology, otolaryngology, and so on.

With the rising demand for endoscopic minimally-invasive technology and continuous improvement in endoscopic processing technology, endoscopic applications have become prominent in almost all departments. The growing demand for diagnosis and endoscopic treatment is expected to further boost the demand for cold disposable biopsy forceps.

Numerous recent technological advances are becoming available to endoscopists. An abundance of new imaging modalities is expected to facilitate early detection of chronic disorders and other pathological entities. Most of these techniques remain investigational and are currently in clinical trials to determine patient benefits.

Companies are expanding their product lines by manufacturing different types of products for a wide range of applications.

For instance, Micro-Tech Endoscopy is mainly engaged in the R&D, manufacturing, and sales of minimally-invasive medical devices, in line with its mission of supporting clinicians with technology and innovation.

Key Takeaways from Cold Disposable Biopsy Forceps Market Study

• Oval cup forceps gained popularity and their sales are expected to grow at a CAGR of 8.8% during the forecast period.

• 2.8 mm diameter have sharpened cups whch ensure superior cutting performance and lead to fewer artefacts and less bleeding. The segment is therefore expected to account for a share of 24.9% in 2021.
• 2300 mm length forceps has precise jaws, no tearing and cause small wound. The segment accounted for the highest share of 37.9% in 2021.
• Upper GI Endoscopy dominated the application segment with the highest market share of 24.9% in 2021.
• Hospitals accounted for the largest share of around 42.0% in 2021 and will remain the end user in the market.

“High prevalence of conditions such as IBD and GERD and growing demand for minimally invasive endoscopic procedures are set to boost the demand for cold disposable biopsy forceps market over the next decade,” says the Future Market Insights analyst.

Get Sample PDF Brochure: 

https://www.futuremarketinsights.com/reports/sample/rep-gb-14240

Who is winning?

The key players are focusing on acquisitions and partnerships with small players and suppliers to increase their market presence. Besides this, they are adopting various strategies to expand their footprint. For instance:

iIn April 2018, Boston Scientific Corporation closed its acquisition of NxThera. The company developed a minimally-invasive therapy the Rezūm system, for patients suffering from symptomatic benign prostatic hyperplasia. With the completion of the acquisition, NxThera became a part of Boston Scientific’s urology and pelvic health business. Moreover, the manufacturers are focusing on research and development activities for developing cold disposable biopsy forceps for various research applications.

In july 2020, ChargePoint and STERIS collaborated to develop a fully validated sterile transfer solution to offer a unique and integrated solution for sterile product transfer.

Some of the leading players in the cold disposable biopsy forceps market include but are not limited to Olympus Corporation, Boston Scientific Corporation, STERIS, CONMED Corporation, Cook Medical, Micro-Tech Endoscopy, Anrei Medical and other companies.

Key Market Segments Covered in Cold Disposable Biopsy Forceps Industry Research

By Product:

• Oval Cup
• Oval Cup with Needle
• Alligator Jaw
• Alligator Jaw with Needle

By Diameter Size:

• 1.2mm
• 1.8mm
• 2.0mm
• 2.4mm
• 2.8mm
• 3.7mm

By Length:

• 1150mm
• 1550mm
• 2300mm

By Application:

• Enteroscopy
• Upper GI Endoscopy
• Lower GI Endoscopy
• Bronchoscopy
• Others

By End User:

• Enteroscopy
• Upper GI Endoscopy
• Lower GI Endoscopy
• Bronchoscopy
• Others

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa (MEA)

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-14240

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusion and Exclusions

3. Market Background

3.1. Macro-Economic Factors

3.1.1. Global GDP Growth Outlook

3.1.2. Global Healthcare Expenditure Outlook

3.1.3. Emerging Countries Healthcare and Development Outlook

3.2. Forecast Factors – Relevance & Impact

3.2.1. Adoption of Device Product

3.2.2. Rising Prevalence of Tumours

3.2.3. Historical growth of key players

3.2.4. New product launches and approvals

3.2.5. COVID-19 Impact

3.2.6.  Reimbursement scenario

3.2.7. Expansion by Leading Manufacturer in Emerging Geographies

3.3. Market Dynamics

3.3.1. Drivers

3.3.2. Restraints

3.3.3. Opportunity Analysis

Inquire Before Buying This Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-14240

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The Saudi Arabia pharmaceutical market is estimated to be valued at US$ 5,209.5 Mn by 2016 end and is expected to expand at a CAGR of 9.0% over the forecast period (2016–2026). The significant rise in lifestyle-related diseases and the developments in healthcare infrastructure are expected to influence the demand for pharmaceuticals in Saudi Arabia. In 2016, the Saudi Arabia pharmaceutical market is anticipated to procure value worth US$ 5,209.5 Mn at a y-o-y growth of 6.0 % over 2015. The mounting demand for branded drug products will continue to incite the growth of the Saudi Arabian pharmaceutical market in 2016.

The demand for pharmaceuticals in Saudi Arabia is expected to register substantial growth owing to the increasing penetration of health insurance companies and the rising incidence rate of non-communicable diseases. Furthermore, the exceptional rise in the per capita income of Saudi Arabia is also expected to foster the demand for branded pharmaceutical drugs. Another key factor driving the growth of the pharmaceutical market in Saudi Arabia is the country’s strategic move to allow 100% FDI in the pharmaceuticals sector. Although, the shortage of profound indigenous research capacity in the pharmaceutical industry and the delayed registration of drug and medicine patents is expected to limit the expansion of the market in 2016 and beyond.

Based on the product type, the pharmaceutical market in Saudi Arabia is expected to witness an upsurge in the prescription-type branded drug products. In terms of market value, the branded drugs are estimated to reach US$ 2,760.8 Mn by 2016-end. The demand for generic drugs is projected to secure steady growth, attributing to the insisting promotion of generic drug adoption by healthcare insurance providers.

On the basis of the diseases, the pharmaceutical drugs used for treatment of cardiovascular diseases will continue exhibiting robust growth in 2016. The demand for cardiovascular medications will continue to surge due to the prominence of circulatory disorders in Saudi Arabia. Additionally, the rising prevalence of disorders related to body sugar levels is expected to make diabetes a rapidly growing disease-based sub-segment in the Saudi Arabia pharmaceutical market.

The pharmaceutical market in Saudi Arabia is also segmented on the basis of distribution channel, where retail pharmacies will continue to account for 80% market share compared to hospital pharmacies. The westernised modernisation of retail pharmacies in Saudi Arabia has led to the availability of a wide range drugs and medicinal products, thereby attaining a considerable growth in the retail pharmacy sub-segment in 2016 and further.

Get Sample PDF Brochure: 

https://www.futuremarketinsights.com/reports/sample/rep-gc-1733

The rising resource potential in Saudi Arabia is projected to positively reform the production environment for pharmaceutical manufacturers. In order to expand the market’s size, structuring alliances with well-established native companies is predicted to be a key strategy for global pharmaceutical leaders. The key players in the Saudi Arabia pharmaceutical market include Novartis AG, SPIMACO, Pfizer Inc., and Glaxosmithkline plc., Jamjoom Pharma,  and Tabuk Pharmaceutical Manufacturing Co. among others.

Long-term Outlook: The Saudi Arabia pharmaceutical market is expected to expand at a CAGR of 9.0% over the forecast period 2016-2026. In terms of market value, the pharmaceutical market in Saudi Arabia is estimated to be worth US$ 12,281.4 Mn by the end of forecast period.

Key Segments Covered

Product Type:

• Prescription Products
  • Branded Drugs
  • Generic Drugs
• Over The Counter (OTC) Products

Disease Type:

• Cardiovascular Diseases
• Diabetes
• Cancer
• Obesity
• Infectious Diseases
• Other Diseases

Distribution Channel:

•  Hospital Pharmacies
• Retail Pharmacies

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gc-1733

Table of Content

1. Research Methodology
2. Assumptions & Acronyms
3. Executive Summary
4. Saudi Arabia Pharmaceutical Market Overview

4.1. Definition

4.2. GCC Pharmaceutical Market Overview

4.3. Value Chain Analysis

4.4. Trade Associations and Trade Fairs

4.5. PESTLE Analysis

4.6. Saudi Arabia Pharmaceuticals Market Overview, 2015–2026

5. Saudi Arabia Pharmaceutical Market-Healthcare Indicators

5.1. Macroeconomic Indicators

5.1.1. Saudi Arabia GDP (US$ Bn) and GDP Growth (%)

5.1.2. GDP Growth (%) Comparison

5.1.3. Healthcare Expenditure (% of GDP), Saudi Arabia

5.1.4. Healthcare Expenditure (% of GDP) Comparison, 2014

5.1.5. Healthcare Expenditure Per Capita (Current US$), 2014

5.1.6. Saudi Arabia Healthcare Budget (US$ Mn) and Y-o-Y Growth (%)

5.1.7. Health Expenditure, (% of GDP) Public Vs. Private Sector

5.1.8. FDI in Saudi Arabia

5.2. Demographic Indicators

5.2.1. Saudi Arabia Population (Mn) and Growth Rate (%)

5.2.2. Saudi Arabia Age Map, 2014

5.3. Healthcare Infrastructure Indicators

5.3.1. Number of Hospitals in Saudi Arabia

5.3.2. Number of Hospital Beds

5.3.3. Number of Healthcare Professionals in Saudi Arabia

5.3.4. Saudi Arabia and International Comparative Analysis / 1,000 Persons, 2013 (or Nearest Year)

Inquire Before Buying This Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gc-1733

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

As per a recent market analysis by Future Market Insights (FMI), the global pharmaceutical lipids market size totaled US$ 4.44 Bn in 2021. With sales growing at a 5.1% CAGR, the market valuation is set to reach US$ 7.70 Bn by 2032.

Increasing demand for various drug formulations to treat chronic diseases across the globe is expected to drive sales of pharmaceutical lipids.

Stringent regulations pertaining to manufacturing and distribution of excipients, mandated by the International Pharmaceutical Excipient Council (IPEC) will improve the manufacturing of better quality ingredients for pharmaceutical drugs.

Furthermore, efforts by governments and regulatory agencies in developed nations, such as the U.S. and the U.K., to streamline the approval process for excipients, are expected to push sales in the market.

Oral solid dosage forms are the dominant mode of delivery in the pharmaceutical lipids market and are the preferred option for many pharmaceutical products due to their cost-effectiveness and patient compliance.

The use of capsules or tablets for a drug delivery offers benefits such as increased physical and chemical stability, convenience of handling, unique brand recognition by color and shape, and controlled-release options.

Most liposomal drugs are based on oral solid drug formulations. Ease of consumption among patients, especially children is expected to boost sales of oral drugs, which will have a direct impact on the sales of pharmaceutical lipids.

For example, around 50% of patients find it difficult to swallow conventional hard solid tablets. This has encouraged drug manufacturers to develop more innovative solid oral product forms, such as effervescent tablets, orally disintegrating granules (ODGs), lozenges, chewable tablets, and instant drinks. This is expected to create substantial demand for liposomal excipients during the forecast period, thereby augmenting the growth in the market.

“Increasing investments in contract manufacturing of pharmaceutical lipids, along with growing demand for oral solid drug formulation is expected to augment the growth in the market over the forecast period,” says an FMI analyst. 

Get Sample PDF Brochure: 

https://www.futuremarketinsights.com/reports/sample/rep-gb-10983

Key Takeaways:

• Based on product type, sales of triglycerides are expected to hold over 44.3% market by 2032 and are expected to increase at a 5.1% CAGR over the forecast period.
• By form, the semi-solid segment is leading with over 60.0% of market share in 2021 and is projected to account 62.7% of the total market share by 2032.
• In terms of source, sales in the semi-synthetic sources segment will grow at a 5.8% CAGR.
• Applications in the conventional lipid-based drug delivery systems (LBDDS) segment accounted for a dominant share of 64.4% in 2021.

• Oral pharmaceutical lipids will emerge as the most widely adopted route of administration. The segment held 40.8% of the total market share in 2021.
• The U.S. will continue dominating the North America pharmaceutical lipids market over the forecast period owing to the presence of a robust healthcare sector.
• Demand in the U.K. pharmaceutical lipids market will surge at a 5.1% CAGR over the assessment period.
• Sales in the India market are slated to increase at a 5.2% CAGR, accounting for a lion’s share in the South Asia pharmaceutical lipids market.

Competition Landscape 

Acquisitions, mergers, expansion, development of an extensive clinical pipeline and product launches are the key strategies adopted by manufacturers to increase the consumer base in various countries. For instance:

• In July 2020, ABITEC announced the acquisition of Larodan AB, a manufacturer and international marketer of state-of-the-art, high-purity research grade lipids. The acquisition expanded ABITEC’s functional lipid product offerings and scientific capabilities to better serve the pharmaceutical, nutritional, and industrial markets.
• In January 2020, BASF completed the acquisition of polyamide business of Solvay.
• In July 2020, Croda International Plc announced the acquisition of Avanti Polar Lipids, Inc., a knowledge-intensive leader in lipid-based drug delivery technologies for the next generation of pharmaceuticals.

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-10983

Key Market Segments Covered in Pharmaceutical Lipids Industry Research

By Product:

• Triglycerides
• Phospholipids
• Sphingolipids
• Cholesterol
• Fatty Acids
• Others

By Source:

• Synthetic
• Semi-synthetic
• Natural

By Form:

• Liquid
• Semi-solid
• Solid

By Application:

• Conventional Lipid-based Drug Delivery Systems
• Self-Emulsifying Drug Delivery Systems
• Self-Microemulsifying Drug Delivery Systems
• Liposomes
• Solid Lipid Nanoparticles
• Nanostructured Lipid Carriers
• Others

By Route of Administration:

• Oral
  • Tablet
  • Solution

• Parenteral
  • Intravenous
  • Intramuscular (Vaccines)
• Topical

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)

Inquire Before Buying This Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-10983

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

According to a recent Future Market Insights (FMI) report, the global femtech market is estimated to hit a valuation of US$ 948.1 Mn in 2021, with a market CAGR of 15.0% during the forecast period (2021-2031). Femtech is a term used for female technology which involves the use of digital health tools including software, diagnostics, products, and services that are targeted at women’s health.

Market demand is set to rise at a steady pace throughout the forecast period, majorly favored by investments outside the boundaries of healthcare towards a branched approach involving domains such as workplace regulations, financial equity, and state legislation.

The primary factor supporting the femtech market to positive expansion in terms of growth and stability is the advent of digitalization and artificial intelligence. Technological advancements such as cloud-based informatics allow personalized solutions, driven by consumer input. This has given rise to affordable and accessible analysis in terms of personal health monitoring and diagnosis.

Key market players have pushed for innovation and accessibility into customized digital solutions. This also includes the introduction of hands-free wearables which are assistive with the regular, day-to-day life of women across the globe.

Additionally, leading product developers in the femtech market work through commercial partners such as department stores, big-box retailers, hospitals, clinics, insurance companies, pharmacies and drugstores, private medical practices and e-commerce platforms to expand product sales prospects.

“The advent of technological improvements in healthcare in the form of devices, applications, services, and products has increased the rate of diagnosis of reproductive disorders in terms of time management and treatments for women. This will aid growth through the upcoming decade,” says the FMI Analyst

Key Takeaways from Femtech Market Study

• Menstrual health applications will drive market growth holding around a third of the market, supported by growing purchases from the working women demographic.
• Diagnostic services are projected to cover about 45% of the global market by 2031. This is aided by the growing accessibility of digital health services
• The U.S. holds a dominant share, valuing at over US$ 357.1 Mn by the end of 2021, supported by the presence of leading players and higher consumer acceptance.
• The U.K. and Germany dominate the Europe market, cumulatively accounting for more than 25% of the regional revenue.
• China is a leading market in East Asia, and is forecast to account for more than 50% of the regional value share owing to a vast consumer base.

Get Sample PDF Brochure: 

https://www.futuremarketinsights.com/reports/sample/rep-gb-11761

Who is Winning?

Some of the leading companies operating in the femtech market are focusing on collaborations with leading institutions for increasing awareness among the population about the adoption of digital health services.

Collaborations with key pharmaceutical companies to launch customized products and services for the growing consumer base has led key players to retain their position in the market while expanding their product portfolio.

• Research collaboration in monitoring fetal heart rates through wearable ECG chips by between Bloomlife and Imec in 2019 has expectantly given rise to superior monitoring capabilities in maternity care.
• Femtech companies have integrated applications for tracking fertility and offer services such as in-vitro fertilization. Additionally, they also offer medical treatments and products such as wearables and hands-free devices.

Femtech by Category

By Service

• Diagnostics
• Monitoring
• Therapeutic

By Application

• General Health and Wellness
• Maternity Care
• Menstrual Health
• Pelvic and Uterine Healthcare
• Cancer and Chronic Disease

By End User

• Direct-to-consumer
• Hospitals
• Surgical Centers
• Fertility Clinics
• Diagnostics Centers

By Region

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• The Middle East and Africa (MEA)

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-11761

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Global Femtech Needs Overview

1.3. Market Evolution

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusion and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Method Innovation / Development Trends

4. Market Background

4.1. Macro-Economic Factors

4.1.1. Global GDP Growth Outlook

4.1.2. Per Capita Healthcare Expenditure Outlook

4.1.3. Global Healthcare Industry Market Outlook

4.2. Forecast Factors – Relevance & Impact

4.2.1. Historic Growth of Key Manufacturers

4.2.2. Adoption of Femtech

4.2.3. Increasing Prevalence of Infectious Disease

4.2.4. Increasing Personalization Services

4.2.5. Rise in Preventive Medicine and Holistic Health

4.2.6. Regulatory Factors

4.2.7. Growing Awareness for Maternity Care

4.2.8. Large Market Opportunity

4.2.9. Reimbursement Policies

4.2.10. Increasing Funding

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunity Analysis

Inquire Before Buying This Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-11761

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

According to the latest research by Future Market Insights (FMI), the global retail clinics market value will exceed US$ 8 billion towards the end of 2028, reflecting a robust CAGR of more than 9.6% during 2022-2028. The revenue generated from the collective demand for retail clinics for point-of-care diagnostics and vaccination accounts for a whopping market value share of nearly 75%, according to FMI’s analysis.

Increasing acceptance of the retail clinics concept, rising awareness about cost related advantages, and improving government support for walk-in clinics will collectively supplement the growth of retail clinics market over the course of coming years. The report opines that the role of governments will be vital in popularization of retail clinics, particularly in developing regional markets.

Convenience & Cost Benefit Collectively Pushing Prospects of Retail Clinics

Retail clinics follow a holistic care approach. In addition, their partnership with various Telehealth vendors such as Teladoc and Doctor on Demand enable healthcare delivery and services at any given place and time. For Instance, an E-commerce channel is being implemented by the US-based CVS Health, one of the leaders in the MinuteClinic chain of retail clinics.

The growing demand for healthcare at relatively lesser service costs will continue to favor the growth of retail clinics market during the forecast period. A lot of major healthcare payers are considering and including retail clinics in their healthcare provider networks, motivating enrolees to opt for these clinics for convenience and quality of care.

Developed regions, the key areas for retail clinics market, account for over 80% of the global revenue. The report envisages significant growth potential in emerging East Asian economies for the retail clinics market, over the projection period.

Get Sample PDF Brochure: 

https://www.futuremarketinsights.com/reports/sample/rep-gb-9254

Retail clinics have been attracting a wide consumer base across the US and the number is actively growing in other key markets such as Europe and China. However, the outreach of retail clinics continues to face challenges due to poor monitoring of penetration into several developing as well as underdeveloped regions. While retail clinics have gained attention since the past few years and are expanding their offerings prudently at a rapid pace, the report highlights that this prompts at an increased need for regulation checks over the coming years.

Retail clinics are positioning themselves to play a crucial role in the delivery of primary care services, worldwide. This trend in the retail clinics market is expected to increase predominantly in developing regions. The potential opportunities will also create long-term challenges facing retailers, clinical laboratories, healthcare policy makers, and pathologists, as suggested by the report.

Key Players Keen on Investing Efforts in Customer Adherence

Patients face difficulties with respect to filing specialty prescriptions, which further affects their will for adherence. CVS Health also piloted a Specialty Connect Program to overcome hindrances in adherence. This program is claimed to enable patients to drop their prescriptions at any given CVS Health store and pick up their medicines once ready. The program has also initiated the delivery of these medicines at their houses or any clinician’s office.

Key Segments Of Retail Clinics Industry Survey

Retail Clinics Market by Application:

• Retail Clinics for Point-of-Care Diagnostics
• Retail Clinics for Clinical Chemistry & Immunoassays
• Retail Clinics for Vaccinations
• Others

Retail Clinics Market by Distribution Channel:

• Retail Clinics in Retail Pharmacy Settings
• Retail Clinics in Drug Stores
• Retail Clinics in Grocery Chains & Big Box Stores

Retail Clinics Market by Ownership Type:

• Hospital-owned Retail Clinics
• Retail-owned Retail Clinics

Retail Clinics Market by Region:

• North America Retail Clinics Market
• Latin America Retail Clinics Market
• Europe Retail Clinics Market
• East Asia Retail Clinics Market
• South Asia & Pacific Retail Clinics Market
• Middle East & Africa (MEA) Retail Clinics Market

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-9254

Table of Content

1. Executive Summary

1.1. Market Overview

1.2. Market Analysis

1.3. Market Trends

1.4. FMI Analysis and Recommendations

2. Market Introduction

2.1. Market Introduction

2.2. Market Definition

2.3. Market Taxonomy

3. Key Market Trends

3.1. Supply Side Market Trends

3.2. Demand Side Market Trends

4. Retail Clinics Market Analysis

4.1. Opportunity Analysis

4.2. Macro-Economic Factors

Inquire Before Buying This Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-9254

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs